Public notice

The therapeutic efficacy results of a candidate immunomodulatory imide drug developed under the Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health (NIH) have been published in the peer-reviewed publication, eLife

관리자 │ 2023-10-13

HIT

180

The therapeutic efficacy results of a candidate immunomodulatory imide drug developed under the Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health (NIH) have been published in the peer-reviewed publication, eLife (June 26, 2020).

 

 

The study, titled, 3,6'-dithiopomalidomide reduces neural loss, inflammation, behavioral deficits in brain injury and microglial activation, may be found here (https://elifesciences.org/articles/54726).

 

 

이전글 이전글이 없습니다.
다음글 Research on the immunomodulatory imide drugs development under the Cooperative R...